Dr. Roy Herbst | Yale Cancer Center | ASCO 2020 Osimertinib/ADAURA trial results
Roy Herbst, MD, PhD, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital talks about new research showing treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations. The findings are to be presented May 31, 2020, during the virtual Scientific Program at the annual meeting of the American Society of Clinical Oncology (ASCO).
